After several years of continuous research and development, notable breakthrough has been made in the field of cancer therapy with the advent of immune checkpoint inhibitors.
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market By Different Cancers
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
After several years of continuous research and development, notable breakthrough has been made in the field of cancer therapy with the advent of immune checkpoint inhibitors. Several immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen (CTLA-4) and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) have gained entry into the market for the management of wide range of cancers. To further enhance their efficacy and to overcome the drug resistance, research studies has evaluated the role of immune checkpoint inhibitor as combination therapy.
In 2015, US FDA approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Later on, this combination was granted approval for the management of several other cancers including renal cell cancer, colorectal cancer, and others. The rational of combining multiple checkpoint inhibitors is that they have different mechanisms of action, with anti – CTLA-4 mainly acting in the lymph node compartment which is responsible for restoring the induction and proliferation of activated T cells, and with anti –PD-1 mainly acting at the periphery of tumor site, preventing the neutralization of cytotoxic T cells by PD-L1 expressing tumor and plasmacytoid dendritic cells in the tumor microenvironment (TME).
Apart from dual immune checkpoint blockade, immune checkpoint inhibitors have also been approved in combination with other cancer targeting regimens including chemotherapy, small molecule inhibitors, or other targeted therapy. For example, Keytruda is approved in combination with Axitinib/ Lenvima/ Chemotherapy + bevacizumab/ Chemotherapy + Trastuzumab across wide range of therapeutic cancers. It is analyzed that immune checkpoint inhibitor combination therapy is currently leading the global combination cancer immunotherapy market owing to large number of combination approved across various cancers and encouraging adoption rate of these in the global market. Our report suggests that this segment will continue to dominate the market throughout the forecast period.
The encouraging response of combination immune checkpoint inhibitors has intensified the competition in the global combination cancer immunotherapy market which is driving acquisitions and in-licensing agreement. The major pharmaceutical companies are striving to expand and diversify their product pipeline. Moreover, companies are forming alliances to synergize their programs to develop combination therapies. For instance in March 2022, Genome and Company announced clinical trial collaboration and supply agreement with Merck to conduct phase-II clinical trial evaluating the safety and efficacy of its immuno-oncology microbiome therapeutic, ‘GEN-001', in combination with Keytruda in patients with biliary tract cancer. GEN-001 is an investigational orally administered immuno-oncology microbiome therapeutic candidate consisting of Lactococcus lactis (L. lactis), a single live bacterial strain isolated from a healthy human.
Another, Enlivex and Mount Sinai Health announced research collaboration for the development of clinical strategies for Allocetra with checkpoint inhibitors. The agreement aims to develop preclinical program to investigate the potential synergies between Allocetra and commercially approved checkpoint inhibitor therapies for select solid cancers. Allocetra developed by Enlivex is macrophage reprogramming immunotherapeutic drug indicated for life-threatening immune mediated disease. The large number of ongoing investments in the global market suggests the promising future of this segment in the forthcoming years.
As per our report findings, the global combination cancer immunotherapy is expected to surpass US$ 15 Billion by 2028. The major factor boosting the growth of market includes the rising prevalence of cancer and unmet need of targeted therapy in its management. In addition, the encouraging response of combination cancer therapy over other approved therapies is another factor propelling the growth of market. Moreover, huge pharmaceutical investments and clinical trials are also boosting the market. The identification of other co-stimulatory immune checkpoints such as LAG3, TIGIT, TIM-3, VISTA, and their potential role in combination therapy will also drive the growth of market during the forecast period.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com